#Pembrolizumab

Ben Westphalen

BenWestphalen

LBA4 @ASCO #ASCO20 plenary session: Thierry Andre presents the results of KEYNOTE-177 (Pembro vs. CTX) in MSI/dMMR #crcsm : Doubling of PFS w. Prembro (. vs . months - HR

Kartik Sehgal

KartikSehgal_MD

Delay/extension of pembro-based Rx for advanced NSCLC expected #COVID19. In preprint @medRxiv, our experience with outcomes in patients who received atleast ≥4 cycles and had delays/extensions. Results hypothesis-generating only but

Dr Tim Clay

drtclay

#ASCO21 #ASCO2021 plenariesLBA 1 Breast - adjuvant PARPi in BRCA+LBA 2 NPC - addition of IO to chemoLBA 3 Cervix - adj chemo following chemoRTLBA 4 Prostate - theranostics -

Bishal Gyawali

oncology_bg

Ok, pembrolizumab first line for mCRC has taken up too much of my time on twitter, so I won’t be engaging on that debate anymore. I can see why some

Nathan A. Pennell MD, PhD, FASCO

n8pennell

THREAD: I have heard a lot of self-righteous indignation about how we would be bankrupting the system with adjuvant targeted treatment for EGFR mutation+ NSCLC pts, so let's take a

Amit Kulkarni

AmitKulkarniMD

#FDA recently approved #pembrolizumab- a tissue agnostic indication in metastatic tumors with high #TMB (>10 mut/MB) using Foundation One Dx companion diagnostic test. I want to share a tweetorial on

Nature Medicine

NatureMedicine

It's #WorldCancerDay and we @NatureMedicine are fortunate to work with the amazing #cancerresearch community to share exciting and impactful #translational and #clinical studies on the prevention, diagnosis and treatment of

Yates Investing

yatesinvesting

$KTOV DD Thread: I will never lie to my followers or lead you astray on purpose. Let’s get started. Consensi IS NOT the main catalyst for KTOVCM-24 IS NOT the

Chris Randone

ChrisRandone

Why today's $KTOV bullish run is just the beginning of a highly anticipated BIG WEEK, why MERCK ($MRK) is leading many to believe they will be the potential collaborating partner